Pneumonitis in association with primary HIV illness.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Pneumonitis in association with primary HIV illness.

Annu Conf Australas Soc HIV Med. 1993 Oct 28-30;5:26 (abstract no. TC-1). Unique Identifier : AIDSLINE ASHM5/94348946
Kelly M; Lloyd A; Jones P; Department of Infectious Diseases, Prince Henry Hospital, Little; Bay, Sydney.

Abstract: A 27 year old homosexual male presented initially with a 5 day illness characterised by fever and rash. Apart from a maculopapular rash there was no physical abnormality. The symptoms resolved spontaneously over a four day period. At presentation P24Ag was positive and then became negative whereas tests for HIV antibody were initially negative and then became positive over a two week period. At presentation the CD4 count was 180 x 10(6)/l and CD8 count was 340 x 10(6)/l. Four weeks after discharge the patient represented with a 7 day febrile illness with dyspnoea and cough. Fine crepitations were heard at the lung bases. The PaO on room air was 73mmHg. The chest x-ray was normal. A bronchoscopy was macroscopically normal. Immunofluorescent studies for Pneumocystis carinii were negative. Bronchoalveolar lavage cell count revealed 60% lymphocytes (73% CD8 and 18% CD4). The peripheral blood CD4 and CD8 cell count were 250 x 10(6)/l and 1190 x 10(6)/l respectively. The patient was commenced on steroids and supplemental oxygen and improved over a three day period. Steroids were subsequently reduced and the patient remained well. Pneumonitis is a rare but significant complication of primary HIV illness which may respond to steroids.

Keywords: Adrenal Cortex Hormones/THERAPEUTIC USE Adult Case Report Combined Modality Therapy CD4-CD8 Ratio CD4-Positive T-Lymphocytes/IMMUNOLOGY Diagnosis, Differential Homosexuality Human HIV Seropositivity/*DIAGNOSIS/DRUG THERAPY/IMMUNOLOGY Leukocyte Count Male Oxygen Inhalation Therapy Pneumonia/*DIAGNOSIS/DRUG THERAPY/IMMUNOLOGY ABSTRACT
941230
M94C4281

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .